General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XICFQ
ADC Name
WO2022253035A1 ADC-27
Synonyms
WO2022253035A1 ADC 27
   Click to Show/Hide
Organization
Sichuan Kelun Pharmaceutical Co., Ltd.
Drug Status
Investigative
Indication
In total 3 Indication(s)
Colorectal cancer [ICD11:2B91]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
Drug-to-Antibody Ratio
7.81
Structure
Antibody Name
19F6_Hu35v1
 Antibody Info 
Antigen Name
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
 Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2022253035A1 ADC-27 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 51.08
%
NCI-N87 cells
Gastric tubular adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 59.14
%
HT-29 cells
Colon adenocarcinoma
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.6
ug/mL
HT-29 cells
Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
1.35
ug/mL
NCI-H1975 cells
Lung adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 51.08% (Day 42) Positive ROR1 expression (ROR1 +++/++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model NCI-N87 CDX model
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 59.14% (Day 32) Positive ROR1 expression (ROR1 +++/++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model HT-29 CDX model
In Vitro Model Colon adenocarcinoma HT-29 cells CVCL_0320
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.60 ug/mL Positive ROR1 expression (ROR1 +++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Colon adenocarcinoma HT-29 cells CVCL_0320
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.35 ug/mL Positive ROR1 expression (ROR1 +++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Lung adenocarcinoma NCI-H1975 cells CVCL_1511
References
Ref 1 Antibody drug conjugate, and preparation method therefor and use thereof; 2022-12-08.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.